The white-coat effect is an independent predictor of myocardial ischemia in resistant hypertension

Blood Pressure

Volumn 23, Issue 5, 2014, Pages 276-280

  Modolo, Rodrigo ^a   Ruggeri Barbaro, Natália ^a   De Faria, Ana Paula ^a   Rodrigues Sabbatini, Andréa ^a   Paganelli, Maria Ondina ^a   Fontana, Vanessa ^a   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Myocardial ischemia; Resistant hypertension; White coat effect

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CROSS-SECTIONAL STUDY; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRACTICE GUIDELINE; QUESTIONNAIRE; RESISTANT HYPERTENSION; SILENT MYOCARDIAL ISCHEMIA; SLEEP DISORDERED BREATHING; WHITE COAT EFFECT; WHITE COAT HYPERTENSION; AGED; ALBUMINURIA; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BODY MASS; COMPLICATION; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; PATHOPHYSIOLOGY; PROGNOSIS;

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; PROGNOSIS; WHITE COAT HYPERTENSION;

EID: 84907062309     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2014.883194     Document Type: Article

References (30)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart Disease and Stroke Statistics-2013 update. A report from the American Heart Association. Circulation. 2013;127:E6-E245.
2. Macmahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood-pressure, stroke, and coronary heart-disease. Prolonged differences in blood-pressure-Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774
3. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080.
4. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: Definition, prevalence, and patient characteristics. J Clin Hypertens. 2012;14:7-12.
5. de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens. 2012;30:1211-1216.
6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment-A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
7. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:1422-1428.
8. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14:1263-1269.
9. Figueiredo VN, Martins LC, Boer-Martins L, de Faria APC, Moraes CD, Santos RC, et al. The white coat effect is not associated with additional increase of target organ damage in true resistant hypertension. Med Clin-Barcelona. 2013; 140:1-5.
10. Gualdiero P, Niebauer J, Addison C, Clark SJ, Coats AJS. Clinical features, anthropometric characteristics, and racial influences on the 'white-coat effect' in a single-centre cohort of1553 consecutive subjects undergoing routine ambulatory blood pressure monitoring. Blood Press Monit. 2000;5:53-57.
11. Lantelme P, Milon H, Gharib C, Gayet C, Fortrat JO. White coat effect and reactivity to stress-Cardiovascular and auto-nomic nervous system responses. Hypertension. 1998;31: 1021-1029.
12. de Souza WA, Sabha M, Favero FD, Bergsten-Mendes G, Yugar-Toledo JC, Moreno H. Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension. J Clin Hypertens. 2009;11:183-191.
13. De Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, Sabha M, Moreno H. Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. Am J Health-Syst Ph. 2007;64: 1955-1961.
14. Drager LF, Genta PR, Pedrosa RP, Nerbass FB, Gonzaga CC, Krieger EM, et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am J Cardiol. 2010;105:1135-1139.
15. Pickering TG, Gerin W, Schwartz AR. What is the white-coat effect and how should it be measured? Blood Press Monit. 2002;7:293-300.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
17. Groppelli A, Omboni S, Parati G, Mancia G. Evaluation of noninvasive blood-pressure monitoring devices Spacelab-90202 and Spacelab-90207 versus resting and ambulatory 24-hour intraarterial blood-pressure. Hypertension. 1992;20: 227-232.
18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
19. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. J Nucl Cardiol. 2002;9:240-245.
20. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death-Differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998;97:535-543.
21. Hansen TW, Kikuya M, Thijs L, Bjorklund-Bodegard K, Kuznetsova T, Ohkubo T, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: A meta-analysis of 7030 individuals. J Hypertens. 2007;25:1554-1564.
22. Grassi G, Bombelli M, Seravalle G, Brambilla G, Dell'Oro R, Mancia G. Role of ambulatory blood pressure monitoring in resistant hypertension. Curr Hypertens Rep. 2013;15: 232-237.
23. Dolan E, Stanton AV, Thom S, Caulfield M, Atkins N, McInnes G, et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients-An Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2009;27:876-885.
24. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: A meta-analysis. J Hypertens. 2007;25: 2193-2198.
25. Nalbantgil I, Onder R, Nalbantgil S, Yilmaz H, Boydak B. The prevalence of silent myocardial ischaemia in patients with white-coat hypertension. J Hum Hypertens. 1998;12:337-341.
26. Boer-Martins L, Figueiredo VN, Demacq C, Martins LC, Consolin-Colombo F, Figueiredo MJ, et al. Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients. Cardiovasc Diabetol. 2011;10.
27. Fagard RH, Stolarz K, Kuznetsova T, Seidlerova J, Tikhonoff V, Grodzicki T, et al. Sympathetic activity, assessed by power spectral analysis of heart rate variability, in white-coat, masked and sustained hypertension versus true normotension. J Hypertens. 2007;25:2280-2285.
28. Neumann SA, Jennings JR, Muldoon MF, Manuck SB. White-coat hypertension and autonomic nervous system dys-regulation. Am J Hypertens. 2005;18:584-588.
29. Evrengul H, Tanriverdi H, Kose S, Amasyali B, Kilic A, Celik T, et al. The relationship between heart rate recovery and heart rate variability in coronary artery disease. Ann Noninvas Electro. 2006;11:154-162.
30. Aarnoudse WH, Botman KJ, Pijls NH. False-negative myo-cardial scintigraphy in balanced three-vessel disease, revealed by coronary pressure measurement. Int J Cardiovasc Intervent. 2003;5:67-71.